Microsoft's one-time retirement program will be open to U.S. workers at the senior director level and below whose years of employment and age add up to 70 or more. The company is also decoupling stock ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Early in the Covid-19 pandemic, the governor of New Jersey made an unusual admission: He’d run out of COBOL developers. The state’s unemployment insurance systems were written in the 60-year-old ...

Solid-state EV batteries, deemed the “holy grail” of battery tech, are moving from the lab to reality, even in the US. Factorial launches solid-state battery program in the US Factorial Energy has ...

IRVINE, Calif. & BOSTON--(BUSINESS WIRE)--Karma Automotive Inc (“Karma Automotive), America’s only full-line ultra-luxury automotive manufacturer, and Factorial ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Factorial, the start-up, said the listing would provide money that would help it bring new solid-state batteries to market as soon as 2027. By Jack Ewing Factorial Energy, which is developing advanced ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Recently, a friend asked me a question that's been floating around every boardroom and business school: "With AI writing code, does programming still matter?" It's a fair question. Generative AI can ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...